Argentina’s ANMAT and Brazil’s ANVISA carry out first secure data exchange

Brazil’s National Health Surveillance Agency (ANVISA) this week announced that it used for the first time the Regulatory Information Secure Exchange (RISE) in the end of last year to exchange medical device inspection registration data with Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT). RISE is part of the Regulatory Exchange Platform-secure (REPS), which was created by the Pan American Health Organization (PAHO) and National Regulatory Authorities (NRAs) in the continent to exchange private documents, and is aimed at streamlining processes and boosting regulatory convergence.

ANVISA also announced a collaboration agreement signed with the French National Agency for Medicines and Health Products (ANSM) for the exchange of information on health products, including policies, practices, standards, laboratory tests, pre-registration evaluations, post-marketing pharmacovigilance, compliance evaluations, as well as clinical trials and therapies regulations.


Recent news
Mexico’s Ministry of Health (SSA) has announced it will update its treatment protocols for the 15 most common types of cancer in the country, as well as diabetes and hypertension.
According to industry insiders, 70% of the ARS 12 billion (USD 318 million) debt of Argentina’s health system with drug retailers comes from anti-cancer medicines.
China’s National Medical Products Administration (NMPA) has waved through two medical devices for marketing.
Chinese pharmaceutical firm China Medical System Holdings Ltd (HKEX.0867) announced a licensing deal with India-based Cadila Healthcare Ltd (Zydus Cadila) in relation to the latter’s ZYAN1 (desidustat).
A team of researchers at the University of Chile (UCH) is working or reprograming aged skin cells to obtain aged neurons that can be used to study the process and consequences of aging on the brain.
  • 1579591960083
  • Chile
  • R&D
China's National Health Commission (NHC) on Monday listed the pneumonia associated with the novel coronavirus (2019-nCoV), known as the Wuhan pneumonia, as a notifiable disease.
Brazil’s National Commission for the Incorporation of Technologies (CONITEC) has included Novartis’s Xolair (omalizumab) into the Unified Health System (SUS)’s coverage for patients with severe asthma, the first product approved for this indication.
Analytics Snapshot

Analytics Snapshot